KIMS Promoter Group Declares No New Share Encumbrances
Krishna Institute of Medical Sciences Limited's promoter group, led by Dr. Bhaskara Rao Bollineni, declared no new share encumbrances as of April 8, 2026. Existing pledges include 10,50,99,645 shares by Dr. Bollineni and 2,42,03,310 shares by Bluebridge Capital Private Limited.
This is a standard disclosure under SEBI regulations confirming the status quo regarding share encumbrances. It does not introduce any new information that would significantly impact the company's stock or operations.
The announcement is a routine regulatory filing confirming no new encumbrances on shares by the promoter group. It does not contain any new positive or negative financial or business developments.
Krishna Institute of Medical Sciences Limited (KIMS) has submitted a declaration regarding the encumbrance of shares under Regulation 31(4) read with Regulation 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Dr. Bhaskara Rao Bollineni, Promoter and Chairman & Managing Director of KIMS Group of Hospitals, along with other members of the Promoter and Promoter Group, has declared that no new encumbrances on shares have been made, directly or indirectly, other than those already disclosed for the financial year ending March 31, 2026.
The announcement details existing pledges by the promoter and promoter group. Dr. Bhaskara Rao Bollineni has 10,50,99,645 shares pledged, representing 26.27% of his holding, with 1,40,00,000 shares pledged at 3.50%. Raiyasri Bollineni has 68,70,015 shares pledged (1.72%), Abhinay Bollineni has 2,36,495 shares pledged (0.06%), Adwik Bollineni has 40,640 shares pledged (0.01%), and Bluebridge Capital Private Limited has 2,42,03,310 shares pledged (6.05%). Sweata Raavi has 39,225 shares pledged (0.00%).
Collectively, the promoter and promoter group has a total of 3,64,89,330 shares encumbered, representing 34.10% of their total holdings, with 1,40,00,000 shares pledged at 3.50%. This declaration confirms the status of share encumbrances as of April 8, 2026.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.